Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Overview

Journal Ann Surg Open

Publisher Wolters Kluwer

Specialty General Surgery

Date 2024 Sep 23

PMID 39310355

Authors

Kai Tai Derek Yeung

Sacheen Kumar

David Cunningham

Long R Jiao

Ricky Harminder Bhogal

Affiliations

Soon will be listed here.

Abstract

Objective: To assess overall survival (OS), compare the effects of neoadjuvant treatment, and describe surgical outcomes for patients undergoing pancreatic resection following chemotherapy and/or chemoradiotherapy (CRT) for borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Background: We approach BR/LA PDAC using chemotherapy followed by selective CRT to the primary site of disease where either the surgical margin remains radiologically threatened following chemotherapy or as a further downstaging treatment.

Methods: Retrospective study of patients between December 2005 and June 2023 at the Royal Marsden Hospital, London, United Kingdom.

Results: A total of 54 patients were included. The OS between R1 and R0 patients was significantly different: 7.5 versus 23 versus 42 versus 51 months for R1 chemo, R1 chemo and CRT, R0 chemo and R0 chemo, and CRT groups, respectively, < 0.001. Similarly, 9 versus 18 versus 42 versus 41 months for N1 chemo, N1 chemo and CRT, N0 chemo and N0 chemo, and CRT groups, respectively, = 0.0026. Multivariable Cox regression model demonstrated that perineural invasion (hazard ratio: 2.88, 95% confidence interval: 1.06-7.81; = 0.038) and perivascular invasion (PVI) (HR: 2.76, 95% CI: 1.24-6.13; = 0.013) were associated with significantly worse OS. Chemo and CRT conferred OS benefit compared to chemo only (7 vs 23 months, = 0.004) in PVI-positive patients.

Conclusions: Neoadjuvant chemotherapy followed by CRT compared to chemotherapy alone for resected BD and LA PDAC was demonstrated to significantly improve median OS, in particular, in patients with R1 resection margins, ypN1 nodal status, and perivascular invasion.

References

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Versteijne E, van Dam J, Suker M, Janssen Q, Groothuis K, Akkermans-Vogelaar J . Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022; 40(11):1220-1230. DOI: 10.1200/JCO.21.02233. View

Pietrasz D, Turrini O, Vendrely V, Simon J, Hentic O, Coriat R . How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Ann Surg Oncol. 2018; 26(1):109-117. DOI: 10.1245/s10434-018-6931-6. View

Jiang L, Qin J, Dai Y, Zhao S, Zhan Q, Cui P . Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat Med. 2024; 30(3):749-761. DOI: 10.1038/s41591-023-02790-x. View

Shah D, Wells A, Cox M, Dawravoo K, Abad J, DSouza A . Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer. Ann Surg. 2024; . PMC: 11263501. DOI: 10.1097/SLA.0000000000006209. View

van Dongen J, Wismans L, Suurmeijer J, Besselink M, de Wilde R, Groot Koerkamp B . The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. HPB (Oxford). 2021; 23(9):1321-1331. DOI: 10.1016/j.hpb.2021.04.027. View

Leonhardt C, Pils D, Qadan M, Jomrich G, Assawasirisin C, Klaiber U . The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Ann Surg. 2023; 279(2):314-322. PMC: 10782940. DOI: 10.1097/SLA.0000000000005874. View

Tempero M, Malafa M, Al-Hawary M, Behrman S, Benson A, Cardin D . Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(4):439-457. DOI: 10.6004/jnccn.2021.0017. View

Ikenaga N, Nakata K, Hayashi M, Nakamura S, Abe T, Ideno N . Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. J Gastrointest Surg. 2023; 27(2):337-346. DOI: 10.1007/s11605-023-05591-2. View

10.

van Dongen J, Suker M, Versteijne E, Bonsing B, Mieog J, de Vos-Geelen J . Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Ann Surg. 2020; 275(5):979-984. DOI: 10.1097/SLA.0000000000004313. View

11.

Hammad A, Hodges J, AlMasri S, Paniccia A, Lee K, Bahary N . Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. JAMA Surg. 2022; 158(1):55-62. PMC: 9685551. DOI: 10.1001/jamasurg.2022.5696. View

12.

Abboud Y, Samaan J, Oh J, Jiang Y, Randhawa N, Lew D . Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Gastroenterology. 2023; 164(6):978-989.e6. PMC: 11364483. DOI: 10.1053/j.gastro.2023.01.022. View

13.

Liu Y, Zhu H, Chen M, Sun W, Li X, Sun Y . Prediction of the lymphatic, microvascular, and perineural invasion of pancreatic neuroendocrine tumors using preoperative magnetic resonance imaging. World J Gastrointest Surg. 2024; 15(12):2809-2819. PMC: 10784819. DOI: 10.4240/wjgs.v15.i12.2809. View

14.

Tempero M . NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):603-605. DOI: 10.6004/jnccn.2019.5007. View

15.

Zou W, Wu D, Wu Y, Zhou K, Lian Y, Chang G . Nomogram predicts risk of perineural invasion based on serum biomarkers for pancreatic cancer. BMC Gastroenterol. 2023; 23(1):315. PMC: 10508025. DOI: 10.1186/s12876-023-02819-y. View

16.

Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B . Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022; 8(9):1263-1270. PMC: 9284408. DOI: 10.1001/jamaoncol.2022.2319. View

17.

Brown Z, Heh V, Labiner H, Brock G, Ejaz A, Dillhoff M . Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022; 110(1):34-42. DOI: 10.1093/bjs/znac354. View

18.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

19.

Tchelebi L, Segovia D, Smith K, Shi Q, Fitzgerald T, Chuong M . Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024; 120(1):111-119. PMC: 11329353. DOI: 10.1016/j.ijrobp.2024.03.013. View

20.

Gemenetzis G, Groot V, Blair A, Laheru D, Zheng L, Narang A . Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2018; 270(2):340-347. PMC: 6985003. DOI: 10.1097/SLA.0000000000002753. View